Antidiabetic Medications Show Potential for Treating Chronic Skin Condition Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a chronic, debilitating inflammatory skin disease characterized by painful nodules, abscesses, and scarring, significantly impacting quality of life. While its exact cause is unknown, metabolic dysfunction and insulin resistance are increasingly recognized as contributing factors in many patients. Current treatments often fall short, leading to a critical need for new therapeutic strategies. This systematic review aimed to evaluate the effectiveness and safety of various antidiabetic medications in managing HS.

The systematic review revealed that several antidiabetic medications demonstrated promising efficacy in improving HS symptoms. Metformin was the most frequently studied agent, showing a mean reduction of 35% in lesion count and a 28% decrease in pain scores across multiple studies. GLP-1 receptor agonists (e.g., liraglutide, semaglutide) also exhibited significant benefits, with one meta-analysis reporting a 43% improvement in disease activity scores and a p<0.01 for overall response rate compared to placebo or standard care. The most compelling finding was that 65% of patients treated with antidiabetic medications experienced a clinically meaningful improvement in their HS, with a 2.5-fold higher likelihood of achieving remission compared to untreated controls. Adverse events were generally mild to moderate, consistent with the known safety profiles of these drugs, with gastrointestinal issues being the most common, affecting approximately 15% of patients.